Phase II, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®), in Adults With Both Human Immunodeficiency Virus (HIV)-1 and CMV Who Are on Potent Combination ART With Conserved Immune Function
Latest Information Update: 08 May 2024
At a glance
- Drugs MVA CMV (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 18 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 14 Dec 2023 Planned End Date changed from 23 Sep 2025 to 14 Oct 2025.
- 14 Dec 2023 Planned primary completion date changed from 23 Sep 2025 to 11 Nov 2024.